Table 4.
Distribution of 334 HIV/HBV co-infected patients on current anti-HBV treatment according to EACS treatment guidelines
| EACS GC regimens | EACS GU regimens | |||
|---|---|---|---|---|
| |
n |
% |
n |
% |
| No indication for anti-HIV therapy |
30 |
68.2 |
14 |
31.8 |
| Indication for anti-HIV therapy° |
202 |
79.2 |
53 |
20.8 |
| Indication for anti-HIV therapy not known§ |
2 |
-- |
-- |
-- |
| Cirrhotic/HCC |
21 |
65.6 |
11 |
34.4 |
| Total | 255 | 76.6 | 78 | 23.4 |
EACS, European AIDS clinical society; GC, guideline consistent; GU, guideline unlisted; °according to EACS guidelines for HCV co-infection [6], 1 patient with triple HCV co-infection on PEG-IFN was considered as “consistent”; §3 patients: 2 on TDF plus LAM/FTC considered as “consistent”, 1 not classifiable.